| scholarly article | Q13442814 |
| P2093 | author name string | Brown C | |
| Morris D | |||
| Andersson BS | |||
| Russell JA | |||
| Stewart D | |||
| Tran HT | |||
| Quinlan D | |||
| Glick S | |||
| Chaudhry A | |||
| Duggan P | |||
| Ruether JD | |||
| Gyonyor E | |||
| P433 | issue | 9 | |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 468-476 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Biology of Blood and Marrow Transplantation | Q15754328 |
| P1476 | title | Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes | |
| P478 | volume | 8 |
| Q86077029 | A modified busulfan and cyclophosphamide preparative regimen for allogeneic transplantation in myeloid malignancies |
| Q47877881 | A novel drug interaction between busulfan and blinatumomab |
| Q35760706 | A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients |
| Q45235834 | A retrospective comparison of BU-fludarabine and BU-CY regimens in elderly patients or in patients with comorbidities who received unmanipulated haploidentical hematopoietic SCT. |
| Q57515100 | A retrospective comparison of autologous and unrelated donor hematopoietic cell transplantation in myelodysplastic syndrome and secondary acute myeloid leukemia: a report on behalf of the Chronic Leukemia Working Party of the European Group for Blood |
| Q37070285 | Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients |
| Q38095833 | Advances in conditioning regimens for older adults undergoing allogeneic stem cell transplantation to treat hematologic malignancies |
| Q46138906 | Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant |
| Q60710884 | Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning |
| Q42870871 | Allogeneic hematopoietic cell transplantation for myelofibrosis: A 10‐year experience at single institution |
| Q37810098 | Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies |
| Q44947826 | Antithymocyteglobulin as prophylaxis of graft failure and graft-versus-host disease in recipients of partially T-cell—depleted grafts from matched unrelated donors: A dose-finding study |
| Q46091045 | Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing |
| Q36151239 | Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a si |
| Q38225489 | Busulfan dosing (Q6 or Q24) with adjusted or actual body weight, does it matter? |
| Q38604900 | Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis |
| Q37554387 | Busulfan in hematopoietic stem cell transplant setting |
| Q34668052 | Busulfan in hematopoietic stem cell transplantation |
| Q37178791 | Busulfan pharmacokinetics, toxicity, and low-dose conditioning for autologous transplantation of genetically modified hematopoietic stem cells in the rhesus macaque model |
| Q36608468 | Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and mu |
| Q43950778 | Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages |
| Q39212390 | Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results |
| Q35057041 | Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation |
| Q37140698 | Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. |
| Q36821646 | Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial |
| Q57100222 | Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation |
| Q88910008 | Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine |
| Q34284225 | Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies |
| Q43194170 | Development of a population pharmacokinetics-based sampling schedule to target daily intravenous busulfan for outpatient clinic administration |
| Q52723665 | Diagnosis of GATA2 haplo-insufficiency in a young woman prompted by pancytopenia with deficiencies of B-cell and dendritic cell development. |
| Q36247606 | Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines |
| Q35574785 | Evaluating the Impact of Antithymocyte Globulin on Lung Function at 1 Year after Allogeneic Stem Cell Transplantation |
| Q33760933 | Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission |
| Q43273886 | Excessive toxicity of once daily i.v. BU, melphalan and thiotepa followed by auto SCT on patients with non-Hodgkin's lymphoma |
| Q42942980 | Favorable outcomes of intravenous busulfan, fludarabine, and 400 cGy total body irradiation-based reduced-intensity conditioning allogeneic stem cell transplantation for acute myelogenous leukemia with old age and/or co-morbidities |
| Q44607762 | Fludarabine and Once-Daily Intravenous Busulfan for Allogeneic Bone Marrow Transplantation for Chediak-Higashi Syndrome |
| Q80237552 | Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in high- and standard-risk leukemic patients |
| Q36742108 | Fludarabine and busulfan as a reduced-toxicity myeloablative conditioning regimen in allogeneic hematopoietic stem cell transplantation for acute leukemia patients |
| Q37738997 | Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients |
| Q34316871 | Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide |
| Q46761676 | Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both? |
| Q48254230 | HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy. |
| Q24600037 | HLA-matched sibling bone marrow transplantation for β-thalassemia major |
| Q37110816 | Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom? |
| Q35924098 | Hematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors. |
| Q37061969 | Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia. |
| Q34479575 | Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome |
| Q33566475 | High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies |
| Q37738524 | High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond |
| Q51355565 | Incidence, characteristics and risk factors of marked hyperbilirubinemia after allogeneic hematopoietic cell transplantation with reduced-intensity conditioning. |
| Q82350298 | Influence of comorbidities on transplant outcomes in patients aged 50 years or more after myeloablative conditioning incorporating fludarabine, BU and ATG |
| Q35136616 | Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies |
| Q35136563 | Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL |
| Q47563781 | Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia |
| Q42175192 | Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies |
| Q44586681 | Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results |
| Q45122639 | Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity |
| Q33652742 | Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. |
| Q84760274 | Intravenous busulfan: a guide to its use as conditioning treatment before transplantation of haematopoietic progenitor cells |
| Q36152695 | Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia? |
| Q39632454 | Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. |
| Q35589035 | Matched related and unrelated donor hematopoietic stem cell transplantation for DOCK8 deficiency. |
| Q90947461 | Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children |
| Q36157233 | Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. |
| Q45306078 | Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring |
| Q34402494 | Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning |
| Q35574536 | Myeloablative conditioning regimens for AML allografts: 30 years later |
| Q38505125 | New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. |
| Q34619834 | Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency |
| Q37828009 | Once daily busulfan cyclophosphamide is well tolerated and effective as a preparative regimen for allogeneic hematopoietic stem cell transplant |
| Q34505185 | Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. |
| Q86852071 | Once-daily i.v. BU-based conditioning regimen before allogeneic hematopoietic SCT: a study of influence of GST gene polymorphisms on BU pharmacokinetics and clinical outcomes in Chinese patients |
| Q37644054 | Optimising the conditioning regimen for acute myeloid leukaemia |
| Q48131864 | Optimization of health-care organization and perceived improvement of patient comfort by switching from intra-venous BU four-times-daily infusions to a once-daily administration scheme in adult hematopoietic stem cell recipients. |
| Q35877266 | Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide |
| Q41201160 | Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification |
| Q48333770 | Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram. |
| Q45006970 | Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes |
| Q34220717 | Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia |
| Q92023463 | Pharmacokinetics analysis results are similar for oral compared to intravenous busulfan in patients undergoing hematopoietic stem cell transplantation, except for the earlier onset of mucositis. A controlled clinical study |
| Q41489633 | Pharmacokinetics study of once-daily intravenous busulfan in conditioning regimens for hematopoietic stem cell transplantation. |
| Q38060264 | Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan. |
| Q35770722 | Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive diseas |
| Q36341861 | Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting. |
| Q39861340 | Physico-chemical stability of busulfan in injectable solutions in various administration packages |
| Q50924228 | Population pharmacokinetics analysis of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation. |
| Q54179395 | Pretransplant conditioning with fludarabine and IV busulfan, reduced toxicity and increased safety without compromising antitumor efficacy and overall treatment effect? |
| Q35600557 | Pretransplant immunosuppression followed by reduced-toxicity conditioning and stem cell transplantation in high-risk thalassemia: a safe approach to disease control |
| Q37370651 | Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation |
| Q36881201 | Prospective validation of a novel dosing scheme for intravenous busulfan in adult patients undergoing hematopoietic stem cell transplantation |
| Q37731525 | Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology |
| Q35800814 | Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT. |
| Q90372460 | Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS |
| Q47572808 | Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome |
| Q53433490 | Reduced-intensity conditioning regimen combined with low-dose total body irradiation in the treatment of myelodysplastic syndrome. |
| Q85680709 | Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial |
| Q45960010 | Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen. |
| Q35568541 | Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I/II trial |
| Q36920394 | Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and M |
| Q56835535 | Similar survival but increased toxicity with a sequential versus concurrent FluBu4 regimen |
| Q54051617 | Single center retrospective analysis of BU-based conditioning regimens in allogeneic transplantation. |
| Q46131298 | Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. |
| Q36548362 | Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents |
| Q46579453 | Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells |
| Q37401427 | Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines |
| Q47124626 | Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity |
| Q47313046 | Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach? |
| Q35060679 | The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan |
| Q36703516 | Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. |
| Q88589771 | Therapeutic salivary monitoring of IV busulfan in patients undergoing hematopoietic stem cell transplantation: a pilot study |
| Q49790702 | Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission. |
| Q44801887 | Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant |
| Q87417746 | Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS |
| Q83379161 | Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party |
| Q33841417 | Unrelated Donor Transplantation for Acute Myelogenous Leukemia in First Remission |
| Q36854385 | Unrelated bone marrow transplantation with a reduced toxicity myeloablative conditioning regimen in Wiskott-Aldrich syndrome |
Search more.